SynBiotic

Management of Hempro International has announced it will file an application with the Münster district court to open preliminary insolvency proceedings. The causes are a marked drop in demand and sales since March 2026 due to worsening economic conditions following geopolitical events. SYNBIOTIC SE is reconsidering the operational development of its subsidiaries as part of restructuring measures and will no longer continue financial support for Hempro; potential impacts on the balance sheet and results are being reviewed. » Más en finanzen.net

The SynBiotic share lost 14.4% in Xetra trading and fell a further almost 20% in after-hours trading. The trigger was the official initiation of a US reclassification of cannabis intended to make medical use easier but not to provide nationwide legalization for recreational purposes. Ahead of this, the stock had already benefited from speculation about a loosening of US rules. » Más en finanzen.net

Synbiotic shares rose by more than 100% since Friday and continued on Wednesday with a gain of over 12% to 3.55 euros; intraday they reached up to 3.78 euros. Earlier in the week the papers had already climbed by as much as 42% after they had marked a record low near 1.50 euros last week. Analyst Harald Hof cited several positive triggers: two smaller capital increases, the insolvency of a non-core subsidiary, sector tailwinds and the entry of the hemp equity fund Cansoul as a new anchor investor in a cash capital increase. » Más en de.investing.com